Phase 2 N=20 Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=96 MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388
Phase 2 N=12 Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Advanced Solid Tumors · Carcinoid · Colorectal Cancer
Primary: Number of Participants With Adverse Events — 2; 1; 1; 1 Participants
Phase 2 N=20 Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Melanoma
Primary: Overall Response Rate (ORR) as Defined by RECIST v1.1 at Week 18 — 20; 56 percentage of participants
Phase 2 N=34 Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Number of Patients Able to Proceed to Transplant — 16; 13; 1; 0 Participants
Phase 2 N=38 A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Multiple Myeloma · Non-Hodgkin's Lymphoma
Primary: Percent of Patients Who Mobilize and Collect at Least Half of the Total Target CD34+ Cell Dose in the First Apheresis — 32.0; 58.3 percentage of participants
Phase 2 N=56 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
Phase 2 N=27 Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients
Stroke · Motor Function
Primary: Changes in Motor Function (Jebsen-Taylor Task) — -214.33; -50.16; -117.98 seconds
Phase 2 N=10 A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
Cervical Cancer
Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) — 100; 100 percentage of participants
Phase 2 N=20 Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Pharmacological Action
Primary: The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment. — 5.35; 5.72 Hypoglycaemic episodes
Phase 2 N=110 MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Phase 2 N=30 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.
Oral Cancer
Primary: Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) — 22 Participants
Phase 2 N=30 Botulinum Toxin A to Treat Arm Tremor
Essential Tremor of the Upper Limbs
Primary: Change From Baseline to Week 4 in Maximum Angular Tremor Amplitude of the Wrist (Injected Limb) — -0.47; 0.07 degree — p=0.144
Phase 2 N=23 Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Adverse Events — 11; 7 participants
Phase 2 N=289 A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Number of Participants Who Achieve SLE Responder Index (SRI) (4) Response — 29; 20; 33; 44 Number of participants — p=0.214